reports
Ultimovacs Announces Poster Presentation at the 2024 American Society ...
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multi...
Ultimovacs ASA – Annual General Meeting held on April 18, 2024
Ultimovacs ASA – Annual General Meeting held on April 18, 2024 Oslo, April 18, 2023: Ultimovacs ASA held its annual general meeting today April 18, 2024. All the matters on the agenda were approved. The following board members were re-elected for a period of one year, and the Board of Directors will consist of the following persons: Jónas Einarsson, Chair of the BoardHenrik Schüssler, board member Kari Grønås, board member Ketil Fjerdingen, deputy board member The Nomination Committee will consist of the following persons until the Annual General Meeting in 2025: Ole Kristian Hjelstue...
- Sean Conroy
Ultimovacs - Steadfast commitment to UV1 progression
Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direc...
Ultimovacs Implements Operational Adjustments to Support Continuous Ad...
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% Th...
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting Oslo, April 15, 2024: In connection with the Annual General Meeting of Ultimovacs ASA to be held on April 18, 2024, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy based voting rights without voting instructions for 9,063,854 shares, representing 26.34% of the total voting rights in the company. The proxies are only valid for the Annual General Meeting on April 18, 2024. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading A...
Ultimovacs – Invitation to Business Update on April 17, 2024
Ultimovacs – Invitation to Business Update on April 17, 2024 NON-REGULATORY PRESS RELEASE Oslo, April 9, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company will host a webcast on April 17, 2024, at 11:00. Ultimovacs’ management will provide a company update emphasizing recent developments and the future potential within the clinical program. The presentation will be followed by a Q&A session. Date: Wednesday, April 17...
Ultimovacs to Present Poster at the American Association for Cancer Re...
Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024 Oslo, April 4, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the TENDU-101 study in patients with relapse after primary radical prostatectomy (NCT04701021) will be presented in a poster at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA. Additionally, a poster with results related to the Phase I ...
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024 Oslo, March 25, 2024, the Board of Directors hereby calls for the Annual General Meeting of Ultimovacs ASA (the "Company") at 14:00 CET on April 18, 2024. The General Meeting will be held electronically. For participation, please log in at . All documents regarding the Annual General Meeting are available at the Company’s website: For further information, please see or contact: Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA Email: Phone: Carlos de Sousa, CEO Email: Phone: ...
Ultimovacs ASA: Mandatory notification of trade by primary insider
Ultimovacs ASA: Mandatory notification of trade by primary insider Oslo, March 22, 2024, Board member Henrik Schüssler and primary insider in Ultimovacs ASA, has today through FireH AS bought 50,000 shares in the company at a price of NOK 6.398 per share. Following this transaction, Henrik Schüssler through FireH AS holds 80,900 shares in Ultimovacs ASA. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. Attachment
Ultimovacs ASA: Annual Report 2023
Ultimovacs ASA: Annual Report 2023 Oslo, 21 March 2024: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of Ultimovacs ASA has approved the Annual Report and ESG Report for 2023. Please find a PDF version of the annual report, as well as the report in European Single Electronic Format (ESEF), as attachments to this release. The Annual Report is also available at the company's website: This information is subject to the disclosure requirements pursuant to Section 5-12 in th...
Ultimovacs ASA: Mandatory notification of trades by primary insider
Ultimovacs ASA: Mandatory notification of trades by primary insider Oslo, 9 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider in Ultimovacs ASA, sold on 8 March 2024, 400,000 shares in the company at an average price of NOK 7.8984 per share. Following these transactions, Langøya Invest AS and closely related parties hold 400,000 shares in Ultimovacs ASA. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act. A...
Ultimovacs ASA: Mandatory notification of trades by primary insider
Ultimovacs ASA: Mandatory notification of trades by primary insider Oslo, 8 March 2024: CGS Holding AS, a closely related party of Leiv Askvig, a board member and primary insider in Ultimovacs ASA, has today sold 140,000 shares in the company at an average price of NOK 7.2507 per share. Following these transactions, CGS Holding AS holds 0 shares in Ultimovacs ASA. Helene Sundt AS, a closely related party of Leiv Askvig, a board member and primary insider in Ultimovacs ASA, has today sold 140,000 shares in the company at an average price of NOK 7.2507 per share. Following these transactions...
- Geir Hiller Holom
Ultimovacs (Sell, TP: NOK4.00) - Top-line results for INITIUM trial
Ultimovacs announced top-line results for the INITIUM trial (malignant melanoma). While the results did not include detailed data, it was clear that the trial did not meet the primary and secondary endpoints. The failed study is a dramatic setback for the company, in our view, as it ends UV1’s prospects in the investigated patient population, while it significantly lowers our confidence in a clinical benefit of the UV1 vaccine across cancer indications. We also struggle to see major positive sha...
Ultimovacs ASA: Mandatory notification of trade by primary insiders
Ultimovacs ASA: Mandatory notification of trade by primary insiders Oslo, 7 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider in Ultimovacs ASA, has today sold 596,006 shares in the company at an average price of NOK 9.5245 per share. Following these transactions, Langøya Invest AS and closely related parties hold 800,000 shares in Ultimovacs ASA. Watrium AS, a closely related party of Haakon Stenrød, a board member and primary insider in Ultimovacs ASA, has today sold 1,780,575 shares in the company at an average price of NOK 9....
- Sean Conroy
Ultimovacs - UV1 hits transitory roadblock with INITIUM top-line
Ultimovacs has announced top-line results for the Phase II INITIUM trial evaluating its cancer vaccine for the treatment of malignant melanoma. While UV1 maintained its desirable safety and tolerability profile, the study did not meet its primary endpoint of progression-free survival (PFS), or the secondary endpoints of overall survival (OS) and objective response rate (ORR). The UV1 arm showed similar performance to the control arm, ipilimumab and nivolumab (the current standard of care). Despi...
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1...
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma With the 18-month minimum follow-up of the patients in the INITIUM trial, the trial did not meet the primary endpoint of prolonging progression-free survival (PFS). Median PFS was not reached in either arm. Evaluation of secondary endpoints did not show a difference in overall survival and objective response rate between the treatment and control armsUV1 maintained its positive safety profile with similar safety a...
- Sean Conroy
Ultimovacs - Peer-reviewed publication reiterates UV1’s potential
Ultimovacs’ results from the Phase II NIPU trial for its universal, off-the-shelf cancer vaccine UV1 in second-line metastatic pleural mesothelioma (MPM) have been published in the European Journal of Cancer, a well-regarded peer-reviewed journal. NIPU is one of the company’s five Phase II programmes for UV1, used in combination with immune checkpoint inhibitors (ICIs). The publication highlighted the growing utility of the combination approach and reiterated the promising efficacy of UV1 with t...
Ultimovacs announces publication of results from NIPU Phase II trial w...
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer NON-REGULATORY PRESS RELEASE The NIPU trial is investigating the effect of adding UV1 vaccine to immunotherapy as second-line treatment of pleural mesothelioma. The results were initially presented at the ESMO Conference in October 2023The publication outlines the full trial results, including observations on UV1’s positive impact on objective response rate, overall survival, and additional data on increased efficacy in defined histological sub...
- Sean Conroy
Ultimovacs - Another ODD boosts the off-the-shelf, universal UV1
Ultimovacs has been granted Orphan Drug designation (ODD) from the European Medicines Agency (EMA) for UV1 in mesothelioma, marking another step forward for the clinical development of its lead universal, off-the-shelf cancer vaccine. This encouraging regulatory designation follows on the heels of the FDA ODD (October 2023) and Fast Track designation (February 2024) for UV1 in this same indication, which helps set the foundation for a potential Phase III programme. A key benefit of EU ODD is the...
Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine...
Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma The Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) was granted based on results from the randomized Phase II clinical trial NIPU, which showed improved overall survival with UV1 in combination with ipilimumab and nivolumab in patients with malignant pleural mesothelioma UV1 has also received U.S. Food and Drug Administration ODD for UV1 in the treatment of patients with mesothelioma and malignant stage IIB-stage IV melanoma Oslo, February 19, 2024: Ult...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.